The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis

被引：21
作者：
Dupuy S.L. [1 ]
Tauhid S. [1 ]
Hurwitz S. [2 ]
Chu R. [1 ]
Yousuf F. [1 ]
Bakshi R. [3 ]
机构：
[1] Department of Neurology, Laboratory for Neuroimaging Research, Partners MS Center, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
[2] Department of Medicine, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
[3] Departments of Neurology and Radiology, Laboratory for Neuroimaging Research, Partners MS Center, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
来源：
Neurology and Therapy | 2016年 / 5卷 / 2期
关键词：
Cerebral gray matter atrophy; Dimethyl fumarate; Multiple sclerosis;
D O I：
10.1007/s40120-016-0054-4
中图分类号：
学科分类号：
摘要：
Introduction: The objective of this pilot study was to compare cerebral gray matter (GM) atrophy over 1 year in patients starting dimethyl fumarate (DMF) for multiple sclerosis (MS) to that of patients on no disease-modifying treatment (noDMT). DMF is an established therapy for relapsing–remitting (RR) MS. Methods: We retrospectively analyzed 20 patients with RRMS at the start of DMF [age (mean ± SD) 46.1 ± 10.2 years, Expanded Disability Status Scale (EDSS) score 1.1 ± 1.2, timed 25-foot walk (T25FW) 4.6 ± 0.8 s] and eight patients on noDMT (age 42.5 ± 6.6 years, EDSS 1.7 ± 1.1, T25FW 4.4 ± 0.6 s). Baseline and 1-year 3D T1-weighted 3T MRI was processed with automated pipelines (SIENA, FSL-FIRST) to assess percentage whole brain volume change (PBVC) and deep GM (DGM) atrophy. Group differences were assessed by analysis of covariance, with time between MRI scans as a covariate. Results: Over 1 year, the DMF group showed a lower rate of whole brain atrophy than the noDMT group (PBVC: −0.37 ± 0.49% vs. −1.04 ± 0.67%, p = 0.005). The DMF group also had less change in putamen volume (−0.06 ± 0.22 vs. −0.32 ± 0.28 ml, p = 0.02). There were no significant on-study differences between groups in caudate, globus pallidus, thalamus, total DGM volume, T2 lesion volume, EDSS, or T25FW (all p > 0.20). Conclusions: These results suggest a treatment effect of DMF on GM atrophy appearing at 1 year after starting therapy. However, due to the retrospective study design and sample size, these findings should be considered preliminary, and require confirmation in future investigations. Funding: Biogen. © 2016, The Author(s).
引用
收藏
页码：215 / 229
页数：14
相关论文
共 75 条
[11]  
Dell'Oglio E., Ceccarelli A., Glanz B.I., Et al., Quantification of global cerebral atrophy in multiple sclerosis from 3T MRI using SPM: the role of misclassification errors, J Neuroimaging, 25, pp. 191-199, (2015)
[12]  
Bermel R.A., Bakshi R., The measurement and clinical relevance of brain atrophy in multiple sclerosis, Lancet Neurol, 5, pp. 158-170, (2006)
[13]  
Durand-Dubief F., Belaroussi B., Armspach J.P., Et al., Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques, AJNR Am J Neuroradiol, 33, pp. 1918-1924, (2012)
[14]  
Maghzi A.H., Revirajan N., Julian L.J., Et al., Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis, Mult Scler Relat Disord, 3, pp. 720-727, (2014)
[15]  
Tauhid S., Neema M., Healy B.C., Weiner H., Bakshi R., MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis, J Neurol Sci, 346, pp. 250-254, (2014)
[16]  
Rojas J.I., Patrucco L., Miguez J., Cristiano E., Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact, Arg Neuropsiquiatr, 74, pp. 235-243, (2016)
[17]  
Vidal-Jordana A., Sastre-Garriga J., Rovira A., Montalban X., Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy, J Neurol, 262, pp. 2617-2626, (2015)
[18]  
Stankiewicz J.M., Glanz B.I., Healy B.C., Et al., Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis, J Neuroimaging, 21, pp. e50-e56, (2011)
[19]  
Khoury S., Bakshi R., Cerebral pseudoatrophy or real atrophy after therapy in multiple sclerosis, Ann Neurol, 68, pp. 778-779, (2010)
[20]  
De Stefano N., Arnold D.L., Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients, Mult Scler, 21, pp. 675-676, (2015)
12345678